UTHR vs. IONS, BMRN, MDGL, ALKS, ALNY, FOLD, SRPT, RDY, CTLT, and KRTX
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Ionis Pharmaceuticals (IONS), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Alnylam Pharmaceuticals (ALNY), Amicus Therapeutics (FOLD), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Karuna Therapeutics (KRTX). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
Ionis Pharmaceuticals currently has a consensus target price of $56.08, suggesting a potential upside of 34.83%. United Therapeutics has a consensus target price of $294.25, suggesting a potential upside of 25.83%. Given United Therapeutics' higher possible upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.
Ionis Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, United Therapeutics had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 20 mentions for United Therapeutics and 5 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.06 beat Ionis Pharmaceuticals' score of 0.68 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 42.31% compared to United Therapeutics' net margin of -46.32%. Ionis Pharmaceuticals' return on equity of 17.72% beat United Therapeutics' return on equity.
Ionis Pharmaceuticals received 110 more outperform votes than United Therapeutics when rated by MarketBeat users. However, 61.66% of users gave United Therapeutics an outperform vote while only 60.09% of users gave Ionis Pharmaceuticals an outperform vote.
Summary
United Therapeutics beats Ionis Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
